Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GNAI3 | P08754 | 1/20 | 0.38 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.38 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.38 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.33 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.32 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.32 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.32 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23807237 | 0.86 | GNAI3 (0.41) | GNAI3GNAO1GNAI1GRIN2BCARM1 | |
| SCHEMBL21106031 | 0.82 | GNAI3 (0.36) | GNAI3GNAO1GNAI1GRIN2BCARM1 | |
| SCHEMBL21106928 | 0.74 | GRIN2B (0.30) | GRIN2B | |
| SCHEMBL25654263 | 0.69 | GRIN2B (0.31) | GRIN2B | |
| SCHEMBL23945545 | 0.69 | GNAI3 (0.35) | GNAI3GNAO1GNAI1GRIN2BCARM1 | |
| SCHEMBL24765661 | 0.68 | — | — | |
| SCHEMBL25754649 | 0.68 | ALDH1A1 (0.40) | GNAI3GNAO1GNAI1L3MBTL1 | |
| SCHEMBL6467124 | 0.66 | — | — | |
| SCHEMBL21106864 | 0.66 | — | — | |
| SCHEMBL24508698 | 0.66 | L3MBTL1 (0.43) | GNAI3GNAO1GNAI1CARM1PRMT6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11779578-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2023-10-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11779578-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | GNAI3 1664/4885GNAO1 2977/4885GNAI1 1458/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.